Image taken from the "Invaders"

Secretariat news

«How to bring research from clinic to innovation - MS?» - 10th of March 2015

On March 10th Nansen Neuroscience Network organized the meeting "Clinic and innovation" in connection with" Nevrodagene". Clinicians, researchers and representatives from the pharmaceutical industry were gathered at Litteraturhuset in Oslo to hear about research, development and innovation related to multiple sclerosis (MS). Read more...

ERC Starting Grants to Norwegian Researchers

Nansen Neuroscience Network would like to congratulate Koen Vervaeke and Hedvig Nordeng for receiving European Research Council (ERC) Starting Grants. ERC Starting Grants are designed to support top up-and-coming research leaders who are at the career stage at which they are starting their own independent research team or programme.

Highlights from ”Towards personalized MS treatment – research on and use of biomarkers” 29th of January 2015

Thursday the 29th of January Nansen Neuroscience Network organized a meeting about multiple sclerosis at Vika Atrium in Oslo. Around 50 participants from academia and industry were gathered to hear about personalized MS treatment and biomarkers.

Member news

"What is communication and why is it important?"

Oslo Cancer Cluster invites members of Nansen Neuroscience Network to breakfast meeting on 15th of April. This meeting is will be of particular interest to start-ups and biotechs. More information

CEO Bjarte Reve invites NNN members to workshop on 9th of April

Dear member of Nansen Neuroscience Network, You are personally invited to an afternoon strategy workshop in Forskningsparken, Oslo. The purpose of the meeting is to engage you in defining the strategy and the main priorities for Nansen Neuroscience Network in the future. Read more...

Save the date for NNN meeting - March 10th

Join our meeting March 10th at Litteraturhuset in Oslo. The topic for this meeting is "Clinic and innovation", and will be of particular interest to clinicians, industry and others with an interest in research, development and innovation related to multiple sclerosis. More information